Jianling Zou

970 total citations
18 papers, 467 citations indexed

About

Jianling Zou is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jianling Zou has authored 18 papers receiving a total of 467 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jianling Zou's work include Cancer Immunotherapy and Biomarkers (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Genetic factors in colorectal cancer (3 papers). Jianling Zou is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Genetic factors in colorectal cancer (3 papers). Jianling Zou collaborates with scholars based in China and Ethiopia. Jianling Zou's co-authors include Jing Gao, Lin Shen, Zhongwu Li, Bin Dong, Tiantian Tian, Zhihao Lü, Yanyan Li, Yan Zhu, Zuhua Chen and Lin Shen and has published in prestigious journals such as Scientific Reports, Frontiers in Immunology and Cancer Letters.

In The Last Decade

Jianling Zou

17 papers receiving 460 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jianling Zou China 14 243 200 122 119 65 18 467
Ruixuan Geng China 12 254 1.0× 234 1.2× 148 1.2× 196 1.6× 58 0.9× 29 556
Andrea Ravelli Italy 10 288 1.2× 200 1.0× 106 0.9× 251 2.1× 36 0.6× 15 543
Alexander G. Raufi United States 11 275 1.1× 156 0.8× 125 1.0× 140 1.2× 111 1.7× 36 457
Haruhito Sakata Japan 13 154 0.6× 251 1.3× 83 0.7× 84 0.7× 81 1.2× 34 483
Hisahito Endo Japan 11 256 1.1× 206 1.0× 89 0.7× 127 1.1× 119 1.8× 30 532
David Borg Sweden 12 391 1.6× 194 1.0× 131 1.1× 177 1.5× 164 2.5× 20 617
Shotaro Fujita Japan 14 336 1.4× 259 1.3× 135 1.1× 99 0.8× 84 1.3× 39 651
Laura L. Meijer Netherlands 12 269 1.1× 192 1.0× 215 1.8× 108 0.9× 128 2.0× 32 477
Fa-Chyi Lee United States 9 193 0.8× 124 0.6× 57 0.5× 156 1.3× 50 0.8× 24 385
Tomohisa Okuno Japan 11 122 0.5× 216 1.1× 143 1.2× 74 0.6× 46 0.7× 27 377

Countries citing papers authored by Jianling Zou

Since Specialization
Citations

This map shows the geographic impact of Jianling Zou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianling Zou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianling Zou more than expected).

Fields of papers citing papers by Jianling Zou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianling Zou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianling Zou. The network helps show where Jianling Zou may publish in the future.

Co-authorship network of co-authors of Jianling Zou

This figure shows the co-authorship network connecting the top 25 collaborators of Jianling Zou. A scholar is included among the top collaborators of Jianling Zou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianling Zou. Jianling Zou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Wang, Yanni, Jianling Zou, Yun Li, et al.. (2022). Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers. Frontiers in Immunology. 13. 987568–987568. 24 indexed citations
3.
Wang, Yujiao, Xi Jiao, Shuang Li, et al.. (2021). Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer. Cancer Biology and Medicine. 19(8). 1139–1149. 8 indexed citations
4.
Lü, Zhihao, Huan Chen, Xi Jiao, et al.. (2021). Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer. Genome Medicine. 13(1). 175–175. 12 indexed citations
5.
Li, Shuang, Jianling Zou, Chang Liu, et al.. (2020). Baseline derived neutrophil-to-lymphocyte ratio as a prognostic biomarker for non-colorectal gastrointestinal cancer patients treated with immune checkpoint blockade. Clinical Immunology. 212. 108345–108345. 21 indexed citations
6.
Lü, Zhihao, Huan Chen, Shuang Li, et al.. (2020). Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer. Journal for ImmunoTherapy of Cancer. 8(2). e000374–e000374. 47 indexed citations
7.
Lin, Xiaoting, Zhi Peng, Xiaojuan Wang, et al.. (2019). Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer. Cell Death and Disease. 10(2). 139–139. 18 indexed citations
8.
Lü, Zhihao, Jianling Zou, Ying Hu, et al.. (2019). Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer. JAMA Network Open. 2(7). e197621–e197621. 29 indexed citations
9.
Zou, Jianling, Ying Liu, Zhentao Liu, et al.. (2018). Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization. Journal of Translational Medicine. 16(1). 15–15. 23 indexed citations
10.
Liu, Zhentao, Ziqi Wang, Shubin Wang, et al.. (2018). Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma. Cancer Letters. 419. 64–74. 40 indexed citations
11.
Zou, Jianling, Zuhua Chen, Zhihao Lü, et al.. (2018). A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo. Cell Death and Disease. 9(6). 661–661. 36 indexed citations
12.
Chen, Zuhua, Zhentao Liu, Wenwen Huang, et al.. (2017). Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways. Journal of Translational Medicine. 15(1). 253–253. 15 indexed citations
13.
Yuan, Jiajia, Yanyan Li, Tiantian Tian, et al.. (2016). Risk prediction for early-onset gastric carcinoma: a case-control study of polygenic gastric cancer in Han Chinese with hereditary background. Oncotarget. 7(23). 33608–33615. 16 indexed citations
14.
Ge, Sai, Qiyue Zhang, Qiong He, et al.. (2016). Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts. Oncology Letters. 12(3). 1763–1768. 11 indexed citations
15.
Zhu, Yan, Tiantian Tian, Zhongwu Li, et al.. (2015). Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer. Scientific Reports. 5(1). 8542–8542. 58 indexed citations
16.
Zhu, Yan, Tiantian Tian, Jianling Zou, et al.. (2015). Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. BMC Cancer. 15(1). 894–894. 26 indexed citations
17.
Li, Na, Qiyue Zhang, Jianling Zou, et al.. (2015). miR-215 promotes malignant progression of gastric cancer by targeting RUNX1. Oncotarget. 7(4). 4817–4828. 52 indexed citations
18.
Dang, Yunzhi, et al.. (2015). PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs). Medical Oncology. 32(4). 111–111. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ruixuan Geng Breakdown of academic impact, for papers by Andrea Ravelli Breakdown of academic impact, for papers by Alexander G. Raufi Breakdown of academic impact, for papers by Haruhito Sakata Breakdown of academic impact, for papers by Hisahito Endo Breakdown of academic impact, for papers by David Borg Breakdown of academic impact, for papers by Shotaro Fujita Breakdown of academic impact, for papers by Laura L. Meijer Breakdown of academic impact, for papers by Fa-Chyi Lee Breakdown of academic impact, for papers by Tomohisa Okuno
Rankless by CCL
2026